Drug intelligence / Profile preview

relmacabtagene autoleucel + sintilimab

Development stage: Unknown
Lead developer: JW Therapeutics
Modality: CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intravenous

Overview

This is a combination therapy consisting of relmacabtagene autoleucel and sintilimab. Relmacabtagene autoleucel (relma-cel) is an autologous anti-CD19 chimeric antigen receptor T-cell (CAR-T) therapy that utilizes a 4-1BB costimulatory domain to target and eliminate CD19-positive B-cells. Sintilimab is a recombinant humanized IgG4 monoclonal antibody that acts as a checkpoint inhibitor by binding to the programmed cell death protein 1 (PD-1) receptor, thereby blocking its interaction with PD-L1 and PD-L2 to restore T-cell anti-tumor activity. The combination is being investigated in Phase II clinical trials led by Sun Yat-sen University for the treatment of relapsed or refractory B-cell malignancies, including diffuse large B-cell lymphoma (DLBCL), mantle cell lymphoma (MCL), and follicular lymphoma (FL).

Brand names: Carteyva + Tyvyt
Other names: Autoleucel-Sun Yat-sen University-diffuse large B-cell lymphoma-mantle cell lymphoma-follicular lymphomaRelmacabtagene Autoleucel Combined With Sintilimab

Targets

CD19 (B lymphocyte antigen CD19)PDCD1 (Programmed cell death protein 1 receptor)

Beyond the preview

Go deeper on relmacabtagene autoleucel + sintilimab.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on relmacabtagene autoleucel + sintilimab.

Explore the full profile